Depression and anxiety symptoms in psoriasis patients compared to a control group without psoriasis—a descriptive study
Background: Due to psychosocial and neurobiological reasons psoriasis is frequently associated with depression and anxiety. The aim of this study was to compare the occurrence of depression and anxiety symptoms in patients with psoriasis with a control group without psoriasis. It was also aimed to study the correlates of these psychological symptoms in patients with psoriasis.
Methods: A cross-sectional, comparison study was done on patients with psoriasis (N=35) and a control group (N=23), who were patients from Otorhinolaryngology department or their caregivers, without psoriasis, attending a tertiary care centre. In the study group, the severity of psoriasis, quality of life, depression and anxiety symptoms were assessed using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 scale (GAD-7) respectively.
Results: 57.1% of cases (95% CI= 39.52-73.24) were found to have symptoms of depression versus 8.7% (95% CI= 1.52-29.51) of controls (p <0.01). 45.7% of cases (95% CI= 29.22 - 63.12) had anxiety symptoms while it was absent in controls (p<0.01). No significant difference between the cases and controls were noted in other variables. Scores of PHQ-9 (ρ=0.825, p<0.01) and GAD-7 (ρ=0.766, p<0.01) were found to have a significant positive correlation with DLQI scores—higher scores suggestive of poorer quality of life. No significant correlation was found between the duration of psoriasis, PASI, PHQ-9 and GAD-7 scores.
Conclusion: There is a high prevalence of depressive and anxiety symptoms in patients with psoriasis compared to a control group without psoriasis. Psychological symptoms have a significant correlation with poorer quality of life of patients with psoriasis.
Lebwohl M. Psoriasis. Lancet 2003; 361:1197–204.
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401–7.
Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010; 76:595.
Gascón MRP, Ribeiro CM, Bueno LM de A, Benute GRG, Lucia MCS de, Rivitti EA, et al. Prevalence of depression and anxiety disorders in hospitalized patients at the dermatology clinical ward of a university hospital. An Bras Dermatol 2012; 87:403–7.
Kumar S, Kachhawha D, Koolwal GD, Gehlot S, Awasthi A. Psychiatric morbidity in psoriasis patients: A pilot study. Indian J Dermatol Venereol Leprol 2011; 77:625.
Singh SM, Narang T, Dogra S, Verma AK, Gupta S, Handa S. Screening for depressive disorders in outpatients with mild to moderate psoriasis: A study from North India. Indian J Dermatol Venereol Leprol2015; 81:148-50.
Lakshmy S, Balasundaram S, Sarkar S, Audhya M, Subramaniam E. A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis. Indian J Psychol Med 2015; 37:434–40.
Reddy VM, Chandrashekar CR. Prevalence of mental and behavioural disorders in India: a meta-analysis. Indian J Psychiatry 1998; 40:149–57.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606–13.
PHQ 9-Malayalam [Internet]. [cited 2018 Sep 6]. Available from: http://www.phqscreeners.com/sites/g/files/g10016261/f/201412/PHQ9_Malayalam%20for%20India.pdf
Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46:266–74.
GAD-7 – Malayalam [Internet]. [cited 2018 Sep 6]. Available from: http://www.phqscreeners.com/sites/g/files/g10016261/f/201412/GAD7_Malayalam%20for%20India.pdf
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA: American Psychiatric Association, 2013.
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51:563–9.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–6.
Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta DermVenereol2005; 85:409–13.
DLQI-Malayalam [Internet]. [cited 2018 Sep 6]. Available from: http://www.cardiff.ac.uk/dermatology/files/2014/07/DLQI-Malayalam.pdf
Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 2017; 176:1028–34.
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J Invest Dermatol 2014; 134:1542–51.
Korkoliakou P, Christodoulou C, Kouris A, Porichi E, Efstathiou V, Kaloudi E, et al. Alexithymia, anxiety and depression in patients with psoriasis: A case-control study. Ann Gen Psychiatry 2014; 13:38.
Tee SI, Lim ZV, Theng CT, Chan KL, Giam YC. A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. J Eur Acad Dermatol Venereol2016; 30:1159–64.
Martínez-García E, Arias-Santiago S, Valenzuela-Salas I, Garrido-Colmenero C, García-Mellado V, Buendía-Eisman A. Quality of life in persons living with psoriasis patients. J Am Acad Dermatol 2014; 71:302–7.
Petraškienė R, Valiukevičienė S, Macijauskienė J. Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina (Kaunas) 2016; 52:238–43.
Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: A study from the US population. J Am Acad Dermatol 2004; 51:704–8.
Rakhesh SV, D’Souza M, Sahai A. Quality of life in psoriasis: a study from south India. Indian J Dermatol Venereol Leprol 2008; 74:600–6.
Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755–60.
Yang Y, Koh D, Khoo L, Nyunt SZ, Ng V, Goh CL. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol 2005; 44:925–9.
Aurangabadkar SJ. Comorbidities in psoriasis. Indian J Dermatol Venereol Leprol 2013; 79:10-7.
Pietrzak D, Pietrzak A, Krasowska D, Makara-Studzińska M, Madej A, Baranowska M, et al. Depressiveness, measured with Beck Depression Inventory, in patients with psoriasis. J Affect Disord 2017; 209:229–34. (29)
Sampogna F, Chren MM, Melchi CF, Pasquini P, Tabolli S, Abeni D, et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006; 154:325–31.
Kim GE, Seidler E, Kimball AB. Effect of age at diagnosis on chronic quality of life and long-term outcomes of individuals with psoriasis. Pediatr Dermatol 2015; 32:656–62.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol 2010; 146:891–5.
Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis Vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16:347–52.
Copyright (c) 2019 Kerala Journal of Psychiatry
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.